Cargando…
Identification of Key Immune-Related Genes in the Treatment of Heart Failure After Myocardial Infarction with Empagliflozin Based on RNA-Seq
PURPOSE: Heart failure is a serious complication after acute myocardial infarction (AMI). It is crucial to investigate the mechanism of action of empagliflozin in the treatment of heart failure. METHODS: A total of 20 wild type (WT) male C57BL6/J mice were used to establish a model of heart failure...
Autores principales: | Zhang, Pei, Wang, Tian-Yu, Luo, Zi-Yue, Ding, Jun-Can, Yang, Qiang, Hu, Peng-Fei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590601/ https://www.ncbi.nlm.nih.gov/pubmed/37872957 http://dx.doi.org/10.2147/JIR.S428747 |
Ejemplares similares
-
Integration of RNA-Seq and Machine Learning Identifies Hub Genes for Empagliflozin Benefitable Heart Failure with Reduced Ejection Fraction
por: Yang, Qiang, et al.
Publicado: (2023) -
The Use of Empagliflozin Post Myocardial Infarction
por: Ravendran, Kapilraj, et al.
Publicado: (2023) -
Empagliflozin in acute myocardial infarction: the EMMY trial( )
por: von Lewinski, Dirk, et al.
Publicado: (2022) -
Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts
por: Mizuno, Masashi, et al.
Publicado: (2018) -
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2020)